Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
Identifieur interne : 005B65 ( Main/Exploration ); précédent : 005B64; suivant : 005B66Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
Auteurs : David T. Dexter [Royaume-Uni] ; Anne E. Holley ; William D. Flitter ; Trevor F. Slater ; F. Raymund Wells [Royaume-Uni] ; Susan E. Daniel [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Chromatography, High Pressure Liquid, Electron Spin Resonance Spectroscopy, Female, Free Radicals, Free radical, Humans, Lipid Peroxidation (physiology), Lipid Peroxides (analysis), Lipid hydroperoxide, Lipid peroxidation, Male, Nerve Degeneration (physiology), Parkinson Disease (pathology), Parkinson's disease, Substantia Nigra (pathology).
- MESH :
- chemical , analysis : Lipid Peroxides.
- chemical : Free Radicals.
- pathology : Parkinson Disease, Substantia Nigra.
- physiology : Lipid Peroxidation, Nerve Degeneration.
- Chromatography, High Pressure Liquid, Electron Spin Resonance Spectroscopy, Female, Humans, Male.
Abstract
Previous studies examining the involvement of oxidative stress in the substantia nigra in Parkinson's disease have measured terminal products of lipid peroxidation or the function of antioxidant defense systems. We report a more specific early marker of lipid peroxidation, lipid hydroperoxides, in a high‐performance liquid chromatography (HPLC) and electron spin resonance (ESR) investigation. HPLC‐chemiluminescent detection revealed two classes of lipid hydroperoxides in brain tissue extracts–free fatty acid hydroperoxides and cholesterol lipid hydroperoxides. Only cholesterol lipid hydroperoxides were consistently detected in all tissue extracts. Cholesterol lipid hydroperoxides had a 10‐fold increase in the Parkinson's disease substantia nigra compared to control subjects. ESR detection of radical degradation products, including those of lipid hydroperoxides, in nigral homogenates incubated with the spin trap N‐t‐butyl‐α‐phenyl nitrone (PBN) showed a marked variation in ESR signal between tissues. Despite the increased levels of lipid hydroperoxides in parkinsonian substantia nigra, there was no overall difference in ESR signal intensity between nigral tissues from controls and from patients with Parkinson's disease. The increased levels of an early component of the peroxidation chain in substantia nigra in Parkinson's disease support the hypothesis of a continuous toxic process involving oxygen radical activity. However, using previously frozen tissue, ESR evidence for increased radical formation could not be demonstrated.
Url:
- https://api.istex.fr/document/B1F20CCFF64050136C8999C916D0190F66415FAC/fulltext/pdf
- https://api.istex.fr/document/0A4F08ABC0DBA29AD58FBBAD2D7DAD1322AE72ED/fulltext/pdf
DOI: 10.1002/mds.870090115
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002053
- to stream Istex, to step Curation: 002053
- to stream Istex, to step Checkpoint: 003F01
- to stream PubMed, to step Corpus: 004B47
- to stream PubMed, to step Curation: 004B47
- to stream PubMed, to step Checkpoint: 004B16
- to stream Ncbi, to step Merge: 004901
- to stream Ncbi, to step Curation: 004901
- to stream Ncbi, to step Checkpoint: 004901
- to stream Main, to step Merge: 008D57
- to stream Istex, to step Corpus: 004617
- to stream Istex, to step Curation: 004617
- to stream Istex, to step Checkpoint: 003F00
- to stream Main, to step Merge: 008D56
- to stream Main, to step Curation: 005B65
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study</title>
<author><name sortKey="Dexter, David T" sort="Dexter, David T" uniqKey="Dexter D" first="David T." last="Dexter">David T. Dexter</name>
</author>
<author><name sortKey="Holley, Anne E" sort="Holley, Anne E" uniqKey="Holley A" first="Anne E." last="Holley">Anne E. Holley</name>
</author>
<author><name sortKey="Flitter, William D" sort="Flitter, William D" uniqKey="Flitter W" first="William D." last="Flitter">William D. Flitter</name>
</author>
<author><name sortKey="Slater, Trevor F" sort="Slater, Trevor F" uniqKey="Slater T" first="Trevor F." last="Slater">Trevor F. Slater</name>
</author>
<author><name sortKey="Wells, F Raymund" sort="Wells, F Raymund" uniqKey="Wells F" first="F. Raymund" last="Wells">F. Raymund Wells</name>
</author>
<author><name sortKey="Daniel, Susan E" sort="Daniel, Susan E" uniqKey="Daniel S" first="Susan E." last="Daniel">Susan E. Daniel</name>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name>
</author>
<author><name sortKey="Marsden, C David" sort="Marsden, C David" uniqKey="Marsden C" first="C. David" last="Marsden">C. David Marsden</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B1F20CCFF64050136C8999C916D0190F66415FAC</idno>
<date when="1994" year="1994">1994</date>
<idno type="doi">10.1002/mds.870090115</idno>
<idno type="url">https://api.istex.fr/document/B1F20CCFF64050136C8999C916D0190F66415FAC/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002053</idno>
<idno type="wicri:Area/Istex/Curation">002053</idno>
<idno type="wicri:Area/Istex/Checkpoint">003F01</idno>
<idno type="wicri:doubleKey">0885-3185:1994:Dexter D:increased:levels:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8139611</idno>
<idno type="wicri:Area/PubMed/Corpus">004B47</idno>
<idno type="wicri:Area/PubMed/Curation">004B47</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004B16</idno>
<idno type="wicri:Area/Ncbi/Merge">004901</idno>
<idno type="wicri:Area/Ncbi/Curation">004901</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004901</idno>
<idno type="wicri:doubleKey">0885-3185:1994:Dexter D:increased:levels:of</idno>
<idno type="wicri:Area/Main/Merge">008D57</idno>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0A4F08ABC0DBA29AD58FBBAD2D7DAD1322AE72ED</idno>
<idno type="url">https://api.istex.fr/document/0A4F08ABC0DBA29AD58FBBAD2D7DAD1322AE72ED/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004617</idno>
<idno type="wicri:Area/Istex/Curation">004617</idno>
<idno type="wicri:Area/Istex/Checkpoint">003F00</idno>
<idno type="wicri:doubleKey">0885-3185:1994:Dexter D:increased:levels:of</idno>
<idno type="wicri:Area/Main/Merge">008D56</idno>
<idno type="wicri:Area/Main/Curation">005B65</idno>
<idno type="wicri:Area/Main/Exploration">005B65</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study</title>
<author><name sortKey="Dexter, David T" sort="Dexter, David T" uniqKey="Dexter D" first="David T." last="Dexter">David T. Dexter</name>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>Parkinson's Disease Society Experimental Research Laboratories, Pharmacology Group, Biomedical Sciences Division, King's College London</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Holley, Anne E" sort="Holley, Anne E" uniqKey="Holley A" first="Anne E." last="Holley">Anne E. Holley</name>
<affiliation><wicri:noCountry code="subField">Middlesex</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Flitter, William D" sort="Flitter, William D" uniqKey="Flitter W" first="William D." last="Flitter">William D. Flitter</name>
<affiliation><wicri:noCountry code="subField">Middlesex</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Slater, Trevor F" sort="Slater, Trevor F" uniqKey="Slater T" first="Trevor F." last="Slater">Trevor F. Slater</name>
<affiliation><wicri:noCountry code="subField">Middlesex</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Wells, F Raymund" sort="Wells, F Raymund" uniqKey="Wells F" first="F. Raymund" last="Wells">F. Raymund Wells</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Parkinson's Disease Society Brain Bank, University Department of Clinical Neurology, Institute of Neurology, National Hospital, Queen Square, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Daniel, Susan E" sort="Daniel, Susan E" uniqKey="Daniel S" first="Susan E." last="Daniel">Susan E. Daniel</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Parkinson's Disease Society Brain Bank, University Department of Clinical Neurology, Institute of Neurology, National Hospital, Queen Square, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Parkinson's Disease Society Brain Bank, University Department of Clinical Neurology, Institute of Neurology, National Hospital, Queen Square, London</wicri:cityArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>Parkinson's Disease Society Experimental Research Laboratories, Pharmacology Group, Biomedical Sciences Division, King's College London</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Marsden, C David" sort="Marsden, C David" uniqKey="Marsden C" first="C. David" last="Marsden">C. David Marsden</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Parkinson's Disease Society Brain Bank, University Department of Clinical Neurology, Institute of Neurology, National Hospital, Queen Square, London</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1994">1994</date>
<biblScope unit="vol">9</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="92">92</biblScope>
<biblScope unit="page" to="97">97</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">B1F20CCFF64050136C8999C916D0190F66415FAC</idno>
<idno type="DOI">10.1002/mds.870090115</idno>
<idno type="ArticleID">MDS870090115</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chromatography, High Pressure Liquid</term>
<term>Electron Spin Resonance Spectroscopy</term>
<term>Female</term>
<term>Free Radicals</term>
<term>Free radical</term>
<term>Humans</term>
<term>Lipid Peroxidation (physiology)</term>
<term>Lipid Peroxides (analysis)</term>
<term>Lipid hydroperoxide</term>
<term>Lipid peroxidation</term>
<term>Male</term>
<term>Nerve Degeneration (physiology)</term>
<term>Parkinson Disease (pathology)</term>
<term>Parkinson's disease</term>
<term>Substantia Nigra (pathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Lipid Peroxides</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Free Radicals</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Lipid Peroxidation</term>
<term>Nerve Degeneration</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Chromatography, High Pressure Liquid</term>
<term>Electron Spin Resonance Spectroscopy</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Previous studies examining the involvement of oxidative stress in the substantia nigra in Parkinson's disease have measured terminal products of lipid peroxidation or the function of antioxidant defense systems. We report a more specific early marker of lipid peroxidation, lipid hydroperoxides, in a high‐performance liquid chromatography (HPLC) and electron spin resonance (ESR) investigation. HPLC‐chemiluminescent detection revealed two classes of lipid hydroperoxides in brain tissue extracts–free fatty acid hydroperoxides and cholesterol lipid hydroperoxides. Only cholesterol lipid hydroperoxides were consistently detected in all tissue extracts. Cholesterol lipid hydroperoxides had a 10‐fold increase in the Parkinson's disease substantia nigra compared to control subjects. ESR detection of radical degradation products, including those of lipid hydroperoxides, in nigral homogenates incubated with the spin trap N‐t‐butyl‐α‐phenyl nitrone (PBN) showed a marked variation in ESR signal between tissues. Despite the increased levels of lipid hydroperoxides in parkinsonian substantia nigra, there was no overall difference in ESR signal intensity between nigral tissues from controls and from patients with Parkinson's disease. The increased levels of an early component of the peroxidation chain in substantia nigra in Parkinson's disease support the hypothesis of a continuous toxic process involving oxygen radical activity. However, using previously frozen tissue, ESR evidence for increased radical formation could not be demonstrated.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Flitter, William D" sort="Flitter, William D" uniqKey="Flitter W" first="William D." last="Flitter">William D. Flitter</name>
<name sortKey="Holley, Anne E" sort="Holley, Anne E" uniqKey="Holley A" first="Anne E." last="Holley">Anne E. Holley</name>
<name sortKey="Slater, Trevor F" sort="Slater, Trevor F" uniqKey="Slater T" first="Trevor F." last="Slater">Trevor F. Slater</name>
</noCountry>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Dexter, David T" sort="Dexter, David T" uniqKey="Dexter D" first="David T." last="Dexter">David T. Dexter</name>
</region>
<name sortKey="Daniel, Susan E" sort="Daniel, Susan E" uniqKey="Daniel S" first="Susan E." last="Daniel">Susan E. Daniel</name>
<name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name>
<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<name sortKey="Marsden, C David" sort="Marsden, C David" uniqKey="Marsden C" first="C. David" last="Marsden">C. David Marsden</name>
<name sortKey="Wells, F Raymund" sort="Wells, F Raymund" uniqKey="Wells F" first="F. Raymund" last="Wells">F. Raymund Wells</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005B65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:B1F20CCFF64050136C8999C916D0190F66415FAC |texte= Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study }}
This area was generated with Dilib version V0.6.23. |